Search Page

1

Cite

Share

[Individual dose adjustment in anticancer chemotherapy].

Gamelin E, Boisdron-Celle M. Gamelin E, et al. Rev Med Interne. 1996;17(7):529-33. doi: 10.1016/0248-8663(96)83087-6. Rev Med Interne. 1996. PMID: 8881376 French. No abstract available.

Cite

Share

2

Cite

Share

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M. Gamelin E, et al. J Clin Oncol. 2008 May 1;26(13):2099-105. doi: 10.1200/JCO.2007.13.3934. J Clin Oncol. 2008. PMID: 18445839 Clinical Trial.

Cite

Share

3

Cite

Share

Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.

Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E. Capitain O, et al. Clin Colorectal Cancer. 2012 Dec;11(4):263-7. doi: 10.1016/j.clcc.2012.05.004. Epub 2012 Jun 9. Clin Colorectal Cancer. 2012. PMID: 22683364 Clinical Trial.

Cite

Share

4

Cite

Share

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.

Boisdron-Celle M, Metges JP, Capitain O, Adenis A, Raoul JL, Lecomte T, Lam YH, Faroux R, Masliah C, Poirier AL, Berger V, Morel A, Gamelin E. Boisdron-Celle M, et al. Semin Oncol. 2017 Feb;44(1):24-33. doi: 10.1053/j.seminoncol.2017.02.007. Epub 2017 Feb 9. Semin Oncol. 2017. PMID: 28395759 Clinical Trial.

Cite

Share

5

Cite

Share

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E. Boisdron-Celle M, et al. Semin Oncol. 2017 Feb;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. Epub 2017 Feb 11. Semin Oncol. 2017. PMID: 28395758 Clinical Trial.

Cite

Share

6

Cite

Share

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

Basseville A, Preisser L, de Carné Trécesson S, Boisdron-Celle M, Gamelin E, Coqueret O, Morel A. Basseville A, et al. Mol Cancer. 2011 Jul 6;10:80. doi: 10.1186/1476-4598-10-80. Mol Cancer. 2011. PMID: 21733184 Free PMC article.

Cite

Share

7

Cite

Share

[Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols].

Boisdron-Celle M, Le Guellec C; Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Boisdron-Celle M, et al. Therapie. 2010 May-Jun;65(3):171-6. doi: 10.2515/therapie/2010023. Epub 2010 Aug 11. Therapie. 2010. PMID: 20699067 Review. French.

Cite

Share

8

Cite

Share

Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.

Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, Gamelin E. Morel A, et al. Mol Cancer Ther. 2006 Nov;5(11):2895-904. doi: 10.1158/1535-7163.MCT-06-0327. Mol Cancer Ther. 2006. PMID: 17121937

Cite

Share

9

Cite

Share

Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype.

Barbado M, Preisser L, Boisdron-Celle M, Verriele V, Lorimier G, Gamelin E, Morel A. Barbado M, et al. Cancer Lett. 2006 Oct 28;242(2):168-79. doi: 10.1016/j.canlet.2005.11.008. Epub 2006 Jan 4. Cancer Lett. 2006. PMID: 16387426

Cite

Share

10

Cite

Share

Niveau de preuve du suivi thérapeutique pharmacologique du 5-fluorouracile au décours de son administration dans le traitement des cancers des voies aérodigestives supérieures et du cancer colorectal.

Boisdron-Celle M, Le Guellec C; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Boisdron-Celle M, et al. Therapie. 2010 May-Jun;65(3):171-6. doi: 10.2515/therapie/2010023. Therapie. 2010. PMID: 27392983 French.

Cite

Share